Results 91 to 100 of about 125,690 (294)

Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis

Journal of Nanobiotechnology
Background Cardiac fibrosis plays a critical role in the progression of various forms of heart disease, significantly increasing the risk of sudden cardiac death.
Xueli Zhao, Yuze Qin, Bowen Li, Yue Wang, Jiao Liu, Bo Wang, Jia Zhao, Jiaqi Yin, Lanlan Zhang, Jing Li, Junzhe Huang, Kun Chen, Liwen Liu, Yuanming Wu   +13 more
doaj   +1 more source

Novel compound mutations in the mitochondrial translation elongation factor (TSFM) gene cause severe cardiomyopathy with myocardial fibro-adipose replacement [PDF]

, 2019
Primary mitochondrial dysfunction is an under-appreciated cause of cardiomyopathy, especially when cardiac symptoms are the unique or prevalent manifestation of disease.
Bonnen, Penelope E, Carbo, Miriam, Cerbelli, Bruna, D'Amati, Giulia, Della Monica, Paola Lilla, Falkous, Gavin, Giordano, Carla, Glasgow, Ruth I C, Hardy, Steven A, He, Langping, Morea, Veronica, Perli, Elena, Pignataro, Maria Gemma, Pisano, Annalinda, Re, Federica, Taylor, Robert W, Zacara, Elisabetta   +16 more
core   +2 more sources

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Myocardial fibrosis in stroke survivors [PDF]

, 2015
Stroke survivors are most likely to die of cardiac death, yet few undergo comprehensive cardiac assessment to look for reversible causes. Myocardial fibrosis (MF) is not only the hallmark of cardiomyopathy, but also a substrate for sudden cardiac death ...
Allgar, V., MacWalter, R., McSwiggan, S., Struthers, A. D., Sze, S., Wong, K., Wong, S.   +6 more
core   +1 more source

Is Hypertrophic Cardiomyopathy Always a Familial and Inherited Disease?

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Jiri Bonaventura, Ethan J. Rowin, Martin S. Maron, Barry J. Maron   +3 more
doaj   +1 more source

Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Longer‐term morbidity post septal myectomy (SM) in obstructive hypertrophic cardiomyopathy has not been well characterized at a national level.
Ahmed Altibi, Miriam Elman, Hailey Volk, Mohammad Alqabani, Michael Butzner, Howard Song, Ahmad Masri   +6 more
doaj   +1 more source

Inter-observer variability for cardiac ultrasound measurements in cats repeated at different time points in early adult life [PDF]

, 2018
A high degree of accuracy is required when using echocardiography to diagnose hypertrophic cardiomyopathy (HCM) in cats, as variation in measurements of 0.5 mm may affect classification of individuals as ‘abnormal’.
Barberet, Chetboul, Gundler, Hansson, Payne, Simpson, Wagner, Wolf   +7 more
core   +2 more sources

Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy [PDF]

, 2010
Paola Melacini, Cristina Basso, Annalisa Angelini, Chiara Calore, F. Bobbo, Barbara Tokajuk, Natalie Bellini, Gessica Smaniotto, M Zucchetto, Sabino Iliceto, Gaetano Thiene, B. J. Maron   +11 more
openalex   +1 more source

Inflammation and genetics in myo‐pericardial diseases: Insights from the Italian Study Group on Cardiomyopathies and Pericardial Diseases

ESC Heart Failure, EarlyView.
Proposed management of myo‐pericardial diseases. A systematic interdisciplinary approach to myo‐pericardial disease is essential to reach a correct diagnosis, starting from multiparametric characterization including EKG, echocardiography with GLS, laboratory exams and CMR or, in case of electric or haemodynamic instability, EMB.
Marco Merlo, Giulia Bassetto, Antonio Cannatà, Alberto Aimo, Camillo Autore, Barbara Bauce, Elena Biagini, Francesco Cappelli, Silvia Castelletti, Flavio D'Ascenzi, Cesare de Gregorio, Giuseppe Limongelli, Francesca Marzo, Beatrice Musumeci, Giacomo Tini, Roberto Pedrinelli, Pasquale Perrone Filardi, Gianfranco Sinagra, Massimo Imazio   +18 more
wiley   +1 more source

Plasma Cardiac Troponin I Concentration and Cardiac Death in Cats with Hypertrophic Cardiomyopathy [PDF]

, 2014
BACKGROUND: The use of cardiac biomarkers to assist in the diagnosis of occult and symptomatic hypertrophic cardiomyopathy (HCM) in cats has been established. There is limited data describing their prognostic utility in cats with HCM.
Abbott, Atkins, Bang, Blume, Chan, Christiaans, Coats, Connolly, Connolly, Connolly, Fernandes, Fox, Fox, Fox, Gersh, Geske, Herndon, Humm, Kittleson, Kubo, Kubo, Langhorn, Lefbom, Lyons, Maron, Maron, Maron, Moreno, Ohno-Machado, Oyama, Paige, Payne, Payne, Peacock, Perna, Perna, Rush, Schober, Schober, Schober, Singletary, Trehiou-Sechi, Wagner, Wess   +43 more
core   +1 more source